Avantor, Inc. $AVTR Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC increased its stake in shares of Avantor, Inc. (NYSE:AVTR) by 418.1% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,006,446 shares of the company’s stock after acquiring an additional 812,203 shares during the period. Squarepoint Ops LLC owned approximately 0.15% of Avantor worth $9,964,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its stake in shares of Avantor by 119.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock valued at $29,000 after purchasing an additional 1,189 shares during the period. Strategic Wealth Investment Group LLC acquired a new stake in Avantor during the 2nd quarter valued at $32,000. Los Angeles Capital Management LLC purchased a new stake in Avantor during the 4th quarter worth $32,000. Osaic Holdings Inc. increased its stake in Avantor by 60.9% during the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after buying an additional 1,064 shares during the period. Finally, SJS Investment Consulting Inc. lifted its holdings in Avantor by 1,599.7% in the 1st quarter. SJS Investment Consulting Inc. now owns 5,235 shares of the company’s stock worth $41,000 after buying an additional 4,927 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

AVTR has been the subject of a number of analyst reports. UBS Group initiated coverage on Avantor in a report on Wednesday. They issued a “neutral” rating and a $16.00 price target for the company. Wells Fargo & Company lifted their price target on shares of Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $13.00 price objective on shares of Avantor in a research report on Thursday, July 30th. Stifel Nicolaus upped their price objective on Avantor from $8.00 to $15.00 and gave the stock a “hold” rating in a research note on Thursday, July 30th. Finally, Evercore set a $10.50 target price on Avantor in a research report on Monday, July 6th. Two analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $12.47.

Avantor Price Performance

Shares of NYSE:AVTR opened at $14.88 on Friday. The firm’s 50 day moving average is $13.01 and its two-hundred day moving average is $10.10. The firm has a market capitalization of $10.06 billion, a P/E ratio of -17.71, a PEG ratio of 11.23 and a beta of 0.89. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. Avantor, Inc. has a 52 week low of $7.26 and a 52 week high of $15.93.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same period in the previous year, the firm posted $0.24 earnings per share. The business’s revenue was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Analysts anticipate that Avantor, Inc. will post 0.81 earnings per share for the current year.

About Avantor

Avantor, Inc (NYSE: AVTR) is a global provider of products and services used in the life sciences, healthcare and advanced technology industries. The company supports research, drug discovery, biopharmaceutical production, clinical and diagnostic activities, and other laboratory-based applications.

Its offerings include laboratory chemicals and reagents, consumables, equipment, instruments, production materials and related services. Avantor also provides supply-chain, procurement and other technical solutions designed to help customers manage laboratory and manufacturing operations.

Avantor serves customers across pharmaceutical and biopharmaceutical companies, healthcare providers, academic and government institutions, medical laboratories and industrial businesses.